局部芦可替尼与口服JAK抑制剂在特应性皮炎患者中的全身风险比较
本研究基于TriNetX网络开展回顾性队列研究,比较特应性皮炎患者使用局部芦可替尼、口服JAK抑制剂或传统局部治疗的不良事件发生率。结果显示局部芦可替尼行动脉血栓和结核发生率显著低于口服JAK抑制剂,且较对照组全因死亡、脑血管意外和静脉血栓栓塞风险降低;口服JAK抑制剂组带状疱疹发生率高于对照组。作者认为局部芦可替尼全身安全性良好,或需重新考虑其黑框警告。
要点
- 局部芦可替尼行动脉血栓和结核发生率显著低于口服JAK抑制剂。
- 局部芦可替尼较对照组全因死亡、脑血管意外和静脉血栓栓塞风险降低。
- 口服JAK抑制剂组带状疱疹发生率高于对照组。
核心结论
- 局部芦可替尼表现出良好的全身安全性,可能值得重新考虑其黑框警告。
研究设计与样本
- 采用TriNetX网络的回顾性队列研究,纳入接受局部芦可替尼、口服JAK抑制剂或传统局部治疗(糖皮质激素和钙调神经磷酸酶抑制剂)的特应性皮炎患者,并使用倾向评分匹配 demographics 和血栓栓塞风险因素。
主要发现
- 局部芦可替尼使用者动脉血栓和结核发生率显著低于口服JAK抑制剂使用者。
- 与对照组相比,局部芦可替尼使用者全因死亡、脑血管意外和静脉血栓栓塞风险降低。
- 口服JAK抑制剂使用者带状疱疹发生率高于对照组。
- 所有组别的不良事件发生率均较低。
临床怎么用
- 临床中可依据本研究结果,在评估特应性皮炎患者使用局部芦可替尼的全身风险时,参考其较低的不良事件发生率。
局限性
- 研究缺乏生存分析,且对照组随访时间较长,可能影响事件检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Topical ruxolitinib is a Janus-activated kinase (JAK) inhibitor used to treat atopic dermatitis. The U.S. Food and Drug Administration issued a boxed warning for topical ruxolitinib, assuming it carries similar risks to oral JAK inhibitors. OBJECTIVE: To compare the incidence of adverse events in patients with atopic dermatitis treated with topical ruxolitinib, oral JAK inhibitors, or conventional topical therapies (corticosteroids and calcineurin inhibitors). METHODS: We conducted a retrospective cohort study using TriNetX. Patients treated with topical ruxolitinib, oral JAK inhibitors, or conventional topical therapies were included. Propensity score matching accounted for demographics and thromboembolic risk factors. Adverse events were compared using t tests with Benjamini-Hochberg correction. RESULTS: Topical ruxolitinib users had significantly lower incidences of arterial thrombosis and tuberculosis compared to oral JAK inhibitor users. Compared to controls, topical ruxolitinib users had decreased risk of all-cause mortality, cerebrovascular accidents, and venous thromboembolism. Oral JAK inhibitor users had a higher incidence of herpes zoster compared to controls. Notably, there were low rates of adverse events across all groups. LIMITATIONS: The study lacks survival analysis and had longer follow-up in control groups, which may influence event detection. CONCLUSION: Topical ruxolitinib demonstrates a favorable systemic safety profile and may warrant reconsideration of its boxed warning.
引用
- Benandi K, Spires A, Hansen A, et al. Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network. J Am Acad Dermatol. 2025. PMID: 40794004. doi:10.1016/j.jaad.2025.06.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。